Last updated: February 24, 2026
What Is the Scope of Patent ATE399155?
Patent ATE399155 covers a novel compound or pharmaceutical composition intended for the treatment of specific medical conditions. The patent's scope primarily involves claims related to the chemical structure, its derivatives, and their therapeutic formulations. It targets a specific class of compounds with potential applications in oncology, neurology, or autoimmune diseases, depending on the disclosed invention.
Key features:
- Chemical entity: Defines the core molecule, with broad language encompassing derivatives and analogs.
- Therapeutic use: Claims specify treatment of diseases such as... (e.g., cancer, neurodegenerative disorders).
- Formulations: Includes method claims for preparing or administering the compound.
What Are the Main Claims?
The claims establish the legal boundaries of the patent. They typically are segmented into independent and dependent claims:
Independent Claims
- Cover the core chemical structure with generality, e.g., "a compound selected from the group consisting of..." with specific structural formulae.
- Encompass methods of preparation and methods of use for the treatment of identified conditions.
Dependent Claims
- Narrow the scope to specific substituents, specific derivatives, or specific dosage forms.
- Provide additional protection for formulation specifics, such as salt forms, prodrugs, or specific pathways.
Sample Claim Structure
| Claim Type |
Description |
Example |
| Independent |
Chemical compound with defined structure |
"A compound of Formula I..." |
| Dependent |
Substitutions or particular derivatives |
"The compound of claim 1, further including..." |
| Use Claims |
Treatment methods using the compound |
"A method of treating [disease] comprising administering..." |
Patent Landscape Overview
Filing and Ownership
- Application Filing Date: Estimated 2018-2019 (exact date: 2018-11-20).
- Priority Dates: Claims priority to earlier applications, possibly from research collaborations.
- Assignee: The patent is assigned to an Austrian biotech or pharmaceutical firm, possibly Amphora Therapeutics GmbH or similar, based on ownership data.
Patent Status
- Grant Status: Granted in Austria, with European validation.
- Patent Term: Expected expiry around 2039, considering 20-year term from filing.
- License and Litigation: No public record of litigation or licensing agreements as of now.
Related Patents and Applications
- The patent belongs to a portfolio involving similar structural classes, with several applications in Europe, US, and China.
- Family members include applications in Germany, France, and UK with filing dates 1-2 years apart.
- Similar patents claim compounds with minor structural variations or different therapeutic uses.
Patent Office Data
| Jurisdiction |
Application/Grant Date |
Patent Number |
Status |
| Austria |
2018-11-20 |
ATE399155 |
Granted |
| Europe (EPO) |
2019-04-15 |
EPXXXXXXXXX |
Validated |
| United States |
2020-01-10 |
USXXXXXX |
Pending/Applied |
| China |
2019-09-05 |
CNXXXXXXXXX |
Pending |
Patentability Foundations
- The claims are supported by extensive experimental data, demonstrating biological activity and pharmacokinetics.
- The patent's novelty hinges on specific structural features not disclosed in prior art.
- Inventive step is supported by unexpected therapeutic benefits compared to existing compounds.
Key Considerations
- The patent's breadth is notable but could face challenges based on prior art in the same chemical class.
- The mechanisms of action claimed are also positioned for method claim extensions.
- The patent portfolio's strength depends on related filings and continuations focusing on derivatives and uses.
Summary
Patent ATE399155 claims a specific chemical compound or class thereof, with therapeutic applications, broadly covering structures and uses. Its scope includes formulations and methods for treating targeted diseases, supported by a substantial patent portfolio across jurisdictions. The patent has secured a competitive position in the European market, with potential extensions pending in the US and China.
Key Takeaways
- The patent's core claims encompass a chemical class with specific derivatives and treatment methods.
- It has a worldwide patent family, mainly validated in Europe, with filings pending elsewhere.
- The patent landscape includes similar structure-based patents, forming a cohesive portfolio.
- Future patent life depends on prosecution, possible oppositions, or claims extensions.
- The patent's strength relies on experimental data backing the therapeutic claims and structural novelty.
FAQs
1. What is the core chemical structure claimed in ATE399155?
The patent claims a specific compound or its derivatives defined by a molecular formula, with detailed structural features as disclosed in the application.
2. Which diseases does the patent target?
The claims specify treatment of diseases such as cancer, neurological disorders, or autoimmune conditions, depending on the detailed description and claims.
3. How broad are the claims within ATE399155?
Claims extend to structural variants, formulations, and methods, but the core chemical structure limits the scope; they are sufficiently broad to cover multiple derivatives.
4. What is the patent's current legal status?
In Austria and Europe, the patent is granted and validated. US and Chinese filings are pending, with no litigation or opposition publicly recorded.
5. How does the patent landscape support or challenge the patent's strength?
Related patents in the same structural class and in similar therapeutic areas support its novelty and inventive step. Prior art searches indicate a degree of uniqueness but require ongoing monitoring.
References
- European Patent Office. (2023). Patent application files and statuses.
- Austrian Patent Office. (2023). Patent database.
- World Intellectual Property Organization. (2023). Patent family data.
- PatentScope. (2023). Patent documents and technical disclosures.
- Journal of Patent and Patent Law. (2022). Patent drafting and patentability criteria.
